One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Global Blood Therapeutics logo
Global Blood Therapeutics GBT
report update icon

Quarterly report 2022-Q2
added 05-30-2026

Global Blood Therapeutics Financial Statements 2021-2011 | GBT

Annual Financial Statements Global Blood Therapeutics

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.82 B 3.07 B 3.81 B 2.45 B 2.45 B 536 M 242 M - - - -

Shares

63 M 61.3 M 58.3 M 51.2 M 42.3 M 33.2 M 12.8 M 1.67 M 1.23 M - -

Historical Prices

28.9 50.1 65.3 47.9 57.9 16.1 18.9 - - - -

Net Income

-303 M -248 M -267 M -174 M -117 M -82.5 M -46.4 M -20.8 M -18.1 M - -

Revenue

195 M 41.3 M 2.11 M - - - - - - - -

Cost of Revenue

3.32 M 1.99 M 48 K - - - - - - - -

Gross Profit

- 122 M 2.06 M - - - - - - - -

Operating Income

-288 M -243 M -281 M -183 M -119 M -83.1 M -46.4 M -20.5 M -15.7 M - -

Interest Expense

-14.9 M -4.38 M 14.5 M 8.55 M - - - - - - -

EBITDA

-282 M -235 M -273 M -178 M -118 M -82 M -45.5 M -19.8 M -15.1 M - -

Operating Expenses

- 366 M 292 M 183 M 119 M 83.1 M 46.4 M 20.5 M 15.7 M - -

General and Administrative Expenses

267 M 211 M 117 M 51.4 M 31.4 M 21 M 9.67 M 3.86 M 2.31 M - -

All numbers in USD currency

Quarterly Income Statement Global Blood Therapeutics

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - 65.6 M 64.8 M 64.6 M 62.9 M 62.3 M 62.1 M 61.9 M 61.6 M 61.1 M 60.8 M 60.6 M 60.1 M 56.5 M 56.2 M 55.6 M 52.1 M 51.7 M 47.8 M 46.1 M 43.3 M 43.1 M 39.1 M 36.6 M 36.4 M 30.4 M 29.4 M 29.4 M 17.3 M 2.22 M 2.05 M 1.95 M 1.7 M 1.59 M - - - - - - - - - - - - -

Net Income

- - -82.5 M -81.4 M - -71 M -69.6 M -74.9 M -61.8 M -59.9 M -52.8 M -73 M -96 M -64.5 M -57.3 M -48.9 M -49.2 M -43.1 M -40.4 M -41.6 M -41.3 M -28.6 M -23.9 M -23.3 M -27.2 M -21 M -17.7 M -16.6 M -15.6 M -14.8 M -8.59 M -7.42 M -5.31 M -5.22 M -5.16 M -5.11 M - - - - - - - - - - - -

Revenue

- - 71.6 M 55.2 M - 52.1 M 47.6 M 39 M 41.3 M 36.9 M 31.5 M 14.1 M 2.11 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - 1.41 M 1.06 M - 830 K 748 K 584 K - 513 K 377 K 135 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - -75.7 M -73.3 M - -67.3 M -66.1 M -71.4 M -59.4 M -58.3 M -52 M -73.5 M -99.2 M -68.7 M -60.8 M -52.5 M -52.1 M -45.5 M -42.5 M -42.7 M -41.9 M -29.2 M -24.4 M -23.7 M -27.5 M -21.1 M -17.8 M -16.7 M -15.6 M -14.8 M -8.6 M -7.42 M -5.31 M -5.2 M -5.13 M -4.87 M - - - - - - - - - - - -

Interest Expense

- - -6.55 M -7.99 M - -3.69 M -3.52 M -3.57 M - -1.57 M -804 K 426 K - 4.2 M 3.48 M 3.6 M - 2.41 M 2.12 M 1.14 M - 623 K 547 K 389 K - 159 K 131 K 117 K - - - - - - - - - - - - - - - - - - - -

EBITDA

- - -72.7 M -71.7 M - -62.9 M -63.2 M -70 M -59.4 M -51.4 M -46.5 M -71.2 M -99.2 M -62.4 M -56.6 M -50.4 M -52.1 M -43 M -41.1 M -42 M -41.9 M -28.2 M -23.8 M -23.2 M -27.5 M -20.3 M -17.3 M -16.5 M -15.6 M -14.2 M -8.21 M -7.24 M -5.31 M -4.71 M -4.81 M -4.87 M - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - 68.7 M 60.8 M 52.5 M - 45.5 M 42.5 M 42.7 M - 29.2 M 24.4 M 23.7 M - 21.1 M 17.8 M 16.7 M - 14.8 M 8.6 M 7.42 M - 5.2 M 5.13 M - - - - - - - - - - - - -

General and Administrative Expenses

- - 81.1 M 74.5 M - 68 M 61.1 M 59 M - 54.5 M 49.1 M 47.7 M - 29.7 M 24.8 M 18.1 M - 12.4 M 10.9 M 12.8 M - 8.23 M 6.15 M 6.44 M - 6 M 4.52 M 4.3 M - 2.67 M 1.51 M 1.3 M - 1.11 M 688 K - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Global Blood Therapeutics GBT
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Global Blood Therapeutics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
- 0.11 % $ 419 M usaUSA
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
$ 8.55 -7.07 % $ 741 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 1.72 -7.77 % $ 11 B australiaAustralia
Shineco, Inc. Shineco, Inc.
TYHT
- -3.90 % $ 97.2 M chinaChina
ORIC Pharmaceuticals ORIC Pharmaceuticals
ORIC
$ 7.66 -4.25 % $ 673 M usaUSA
Millendo Therapeutics, Inc. Millendo Therapeutics, Inc.
MLND
- -5.36 % $ 20.2 M usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
$ 3.9 0.78 % $ 161 M israelIsrael
Certara Certara
CERT
$ 11.25 1.72 % $ 1.8 B usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
$ 0.63 -4.8 % $ 408 K israelIsrael
Intec Pharma Ltd Intec Pharma Ltd
NTEC
- -12.45 % $ 17.7 M israelIsrael
Anika Therapeutics Anika Therapeutics
ANIK
$ 13.74 6.89 % $ 197 M usaUSA
Prothena Corporation plc Prothena Corporation plc
PRTA
$ 8.38 1.39 % $ 451 M usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.46 2.6 % $ 3.01 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
$ 3.0 2.92 % $ 192 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
$ 1.7 -2.3 % $ 2.23 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 67.94 -3.04 % $ 7.06 B usaUSA
Progenity, Inc. Progenity, Inc.
PROG
- -3.47 % $ 164 M usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 2.84 -0.7 % $ 1.93 M chinaChina
Genprex Genprex
GNPX
$ 1.73 3.56 % $ 1.61 M usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
- 1.52 % $ 136 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 21.27 -1.71 % $ 33.6 B japanJapan
Protara Therapeutics Protara Therapeutics
TARA
$ 2.33 0.22 % $ 99.8 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.0 -24.81 % $ 89.6 M franceFrance
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
- -1.19 % $ 28.7 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 61.57 5.22 % $ 11.8 B usaUSA
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 72.74 0.15 % $ 11.3 B usaUSA
Matinas BioPharma Holdings Matinas BioPharma Holdings
MTNB
$ 0.91 6.35 % $ 4.98 M usaUSA
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
$ 8.21 -5.52 % $ 175 K usaUSA
Milestone Pharmaceuticals Milestone Pharmaceuticals
MIST
$ 0.46 10.45 % $ 48.9 M canadaCanada
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 42.18 -1.04 % $ 48.3 B israelIsrael
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 47.99 6.46 % $ 5.5 B usaUSA
Lipocine Lipocine
LPCN
$ 1.54 -3.75 % $ 8.39 M usaUSA
Seres Therapeutics Seres Therapeutics
MCRB
$ 1.45 2.48 % $ 12.8 M usaUSA
Madrigal Pharmaceuticals Madrigal Pharmaceuticals
MDGL
$ 398.15 -5.65 % $ 8.93 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.38 -25.41 % $ 11.1 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
$ 3.4 5.43 % $ 203 M franceFrance
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 8.3 -1.89 % $ 668 M usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 13.55 0.26 % $ 1.83 B usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 62.05 -2.51 % $ 1.67 B usaUSA
IDEAYA Biosciences IDEAYA Biosciences
IDYA
$ 26.13 -4.64 % $ 2.31 B usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
$ 2.96 1.9 % $ 232 M israelIsrael
Lantern Pharma Lantern Pharma
LTRN
$ 0.33 -10.93 % $ 3.6 M usaUSA
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 1.8 -1.91 % $ 113 M usaUSA
Ocugen Ocugen
OCGN
$ 0.73 -2.88 % $ 228 M usaUSA
Oncolytics Biotech Oncolytics Biotech
ONCY
$ 0.44 15.71 % $ 42.2 M canadaCanada
Minerva Neurosciences Minerva Neurosciences
NERV
$ 2.18 0.93 % $ 18.5 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.07 -1.04 % $ 465 M israelIsrael
Neurocrine Biosciences Neurocrine Biosciences
NBIX
$ 162.75 -1.91 % $ 16.2 B usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
$ 26.8 -2.37 % $ 1.28 T franceFrance
Mereo BioPharma Group plc Mereo BioPharma Group plc
MREO
$ 0.29 5.5 % $ 231 M britainBritain